Clinical Trial Update: An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase Ib/II trial evaluating ribociclib with trastuzumab or T-DM1 in advanced/metastatic HER2-positive breast cancer; study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)
• T-DM1 (ado-trastuzumab emtansine)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-03